Tiny lab-grown models of human immune systems are helping researchers understand why cancer patients struggle to fight ...

When thinking about the immune system, most people think about B and T cells and how they can be trained to recognize ...

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

However, patients can survive without B cells. With solid tumors ... immunosuppressive microenvironment that "can shut down ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

Multiple players are exploring whether modalities designed to combat B cell malignancies can be repurposed against lupus, ...

“We're trying to target this pre-programmed subset of B cells,” Scharffenberger said. “If you're able to target them ...

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement ... including 51% of patients with ...